These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 28368373)
1. Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? Kharfan-Dabaja MA; El-Jurdi N; Ayala E; Kanate AS; Savani BN; Hamadani M Bone Marrow Transplant; 2017 Nov; 52(11):1487-1494. PubMed ID: 28368373 [TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369 [TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
4. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas. Shustov A Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning. Kim I; Lee KH; Choi Y; Keam B; Koo NH; Yoon SS; Yoo KY; Park S; Kim BK J Korean Med Sci; 2007 Apr; 22(2):227-34. PubMed ID: 17449929 [TBL] [Abstract][Full Text] [Related]
6. A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations. Atilla E; Ataca Atilla P; Demirer T Balkan Med J; 2017 Jan; 34(1):1-9. PubMed ID: 28251017 [TBL] [Abstract][Full Text] [Related]
8. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144 [TBL] [Abstract][Full Text] [Related]
9. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000 [TBL] [Abstract][Full Text] [Related]
10. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Tomblyn M; Brunstein C; Burns LJ; Miller JS; MacMillan M; DeFor TE; Weisdorf DJ Biol Blood Marrow Transplant; 2008 May; 14(5):538-45. PubMed ID: 18410896 [TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. Kharfan-Dabaja MA; Reljic T; El-Asmar J; Nishihori T; Ayala E; Hamadani M; Kumar A Future Oncol; 2016 Nov; 12(22):2631-2642. PubMed ID: 27381652 [TBL] [Abstract][Full Text] [Related]
12. Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Gisselbrecht C; Bethge W; Duarte RF; Gianni AM; Glass B; Haioun C; Martinelli G; Nagler A; Pettengell R; Sureda A; Tilly H; Wilson K Bone Marrow Transplant; 2007 Dec; 40(11):1007-17. PubMed ID: 17922042 [TBL] [Abstract][Full Text] [Related]
13. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459 [TBL] [Abstract][Full Text] [Related]
14. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML; Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571 [TBL] [Abstract][Full Text] [Related]
15. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. Shimoni A; Nagler A Best Pract Res Clin Haematol; 2011 Sep; 24(3):369-79. PubMed ID: 21925090 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation. Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192 [TBL] [Abstract][Full Text] [Related]
17. Hematopoietic cell transplantation for lymphomas. Ayala E; Tomblyn M Cancer Control; 2011 Oct; 18(4):246-57. PubMed ID: 21976243 [TBL] [Abstract][Full Text] [Related]
18. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. Sengsayadeth S; Savani BN; Blaise D; Malard F; Nagler A; Mohty M Haematologica; 2015 Jul; 100(7):859-69. PubMed ID: 26130513 [TBL] [Abstract][Full Text] [Related]